The Medical Letter on Drugs and Therapeutics
Sucroferric Oxyhydroxide (Velphoro) for Hyperphosphatemia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Most patients with end-stage renal disease develop hyperphosphatemia, which can lead to secondary hyperparathyroidism, vascular calcification, and cardiovascular mortality. The FDA has approved sucroferric oxyhydroxide (Velphoro – Fresenius Medical Care), a chewable phosphate binder, for treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. It is the first iron-based phosphate binder to be approved for this indication.

STANDARD TREATMENT — Dietary restriction of phosphate and dialysis treatment are somewhat effective in lowering serum phosphorus levels, but addition of an oral phosphate binder is often needed. Whether phosphate-binding drugs can improve clinical outcomes has not been established.

The anion-exchange resin sevelamer carbonate (Renvela)1 and the calcium-based phosphate binder calcium acetate (PhosLo, ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Sucroferric Oxyhydroxide (Velphoro) for Hyperphosphatemia
Article code: 1449b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian